Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P‐Gp: Drug Interaction Studies and Physiologically‐Based Pharmacokinetic Analysis

ABSTRACT Tepotinib is a highly selective, potent, mesenchymal‐epithelial transition factor (MET) inhibitor, approved for the treatment of non‐small cell lung cancer harboring MET exon 14 skipping alterations. This work aimed to investigate the potential for drug–drug interactions with strong inhibit...

Cijeli opis

Bibliografski detalji

Glavni autori:	Rainer Strotmann, Christian Lüpfert, Axel Krebs‐Brown, Alice Ke, Matthias Boedding, Jürgen Heuer, Karen Rowland Yeo, Lisa Benincosa, Karthik Venkatakrishnan
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2025-07-01
Serija:	Clinical and Translational Science
Teme:	cancers clinical trials CYP drug–drug interactions induction inhibitors
Online pristup:	https://doi.org/10.1111/cts.70273
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!